Kenneth Jones, MD
Family Medicine · North Charleston, SCNPI 1548344096
Payments from drug & device makers
Across 65 payments — averaging $28.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$493
- Novo Nordisk$231
- Organogenesis Inc.$211
- AbbVie$172
- Gilead$118
- Novartis$116
- plus $525 from 13 others
Across 1 payment — averaging $150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$150
What the payments were for
- Food & beverage$1,865100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $493 |
| Novo Nordisk | 8 | $231 |
| Organogenesis Inc. | 2 | $211 |
| AbbVie(2 entities) | 9 | $172 |
| Gilead | 2 | $118 |
| Novartis | 6 | $116 |
| Exact Sciences | 5 | $79 |
| Organon | 5 | $66 |
| Lilly USA, LLC | 3 | $64 |
| Neurocrine Biosciences, Inc. | 3 | $60 |
| Hologic Sales And Service, LLC | 2 | $59 |
| Indivior Inc. | 3 | $52 |
| GSK | 2 | $29 |
| Theratechnologies Inc. | 1 | $26 |
| Viatris Specialty LLC | 1 | $24 |
| Dexcom, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Alkermes, Inc. | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PURAPLY WOUND MATRIX$105
- Apligraf$105
- BREZTRI$101
How this compares
$1,865 in reported general payments places this provider in the 70th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 97 | $132,987 |
| FarxigaDapagliflozin Propanediol | 80 | $112,845 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 15 | $68,131 |
| LinzessLinaclotide | 72 | $65,550 |
| EliquisApixaban | 50 | $63,752 |
| JardianceEmpagliflozin | 43 | $53,809 |
| JanuviaSitagliptin Phosphate | 39 | $47,441 |
| EntrestoSacubitril/Valsartan | 31 | $40,198 |
| MounjaroTirzepatide | 14 | $29,017 |
| Spiriva HandihalerTiotropium Bromide | 20 | $27,801 |
| TrulicityDulaglutide | 21 | $21,563 |
| SymbicortBudesonide/Formoterol Fumarate | 58 | $20,426 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 33 | $18,893 |
| XareltoRivaroxaban | 12 | $18,133 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $17,219 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $493 | $133,270138 claims |
| Novo NordiskOzempic | $231 | $132,98797 claims |
| MerckJanuvia, Janumet, Janumet Xr | $14 | $73,91069 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $17 | $72,70276 claims |
| GileadBiktarvy | $118 | $68,13115 claims |
| AbbVieLinzess | $172 | $65,55072 claims |
| Lilly USA, LLCMounjaro, Trulicity | $64 | $50,58035 claims |
| NovartisEntresto | $116 | $40,19831 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $29 | $29,11444 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in North Charleston
- Kelly MoralesNorth Charleston$6.5M
- Martha BuchananNorth Charleston$143K
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.